Future Outlooks in the Treatment of Advanced RCC
Experts close the discussion by sharing insights on the future in advanced RCC, emphasizing the development of emerging agents and combination regimens for the treatment landscape.
EP: 1.The Evolution of Advanced Renal Cell Carcinoma
EP: 2.CLEAR Trial: Lenvatinib plus Pembrolizumab in Advanced RCC
EP: 3.Tackling Toxicity Management in Combination Regimens for Advanced RCC
EP: 4.Impact of Treatment Selection and Real-World Outcomes in Advanced RCC
EP: 5.Data Updates in Advanced RCC from 2023 IKCS: North America
EP: 6.Future Outlooks in the Treatment of Advanced RCC
This is a video synopsis/summary of a Post Conference Perspectives featuring Brian Rini, MD, and Hans Hammers, MD, PhD.
As they conclude, Rini and Hammers briefly discuss additional kidney cancer agents and studies presented at the 2023 International Kidney Cancer Symposium (IKCS). These include nivolumab with relatlimab and a phase 3 trial in metastatic papillary renal cell carcinoma.
Regarding future development of the novel tyrosine kinase inhibitor (TKI) zanzalintinib, Hammers proposes it may have a role in frontline triplets with immunotherapy. Given its favorable tolerability shown thus far, he believes it could be used in regimens like ipilimumab/nivolumab. Rini agrees triplets remain an active area of kidney cancer research.
While early efficacy signals for zanzalintinib are encouraging, both experts reiterate that substantially more data is still required to determine where it fits among existing therapies. But it may address an unmet need for a tolerable TKI backbone for immunotherapy combinations.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
